Full metadata record
DC FieldValueLanguage
dc.creatorSimon-Yarza, T. (Teresa)-
dc.creatorFormiga, F.R. (Fabio R.)-
dc.creatorTamayo, E. (Esther)-
dc.creatorPelacho, B. (Beatriz)-
dc.creatorProsper-Cardoso, F. (Felipe)-
dc.creatorBlanco-Prieto, M.J. (María José)-
dc.date.accessioned2013-06-10T16:48:32Z-
dc.date.available2013-06-10T16:48:32Z-
dc.date.issued2013-
dc.identifier.citationSimon-Yarza T, Formiga FR, Tamayo E, Pelacho B, Prosper F, Blanco-Prieto MJ. PEGylated-PLGA microparticles containing VEGF for long term drug delivery. Int J Pharm 2013 JAN 2;440(1):13-18es_ES
dc.identifier.issn0378-5173-
dc.identifier.urihttps://hdl.handle.net/10171/29347-
dc.description.abstractThe potential of poly(lactic-co-glycolic) acid (PLGA) microparticles as carriers for vascular endothelial growth factor (VEGF) has been demonstrated in a previous study by our group, where we found improved angiogenesis and heart remodeling in a rat myocardial infarction model (Formiga et al., 2010). However, the observed accumulation of macrophages around the injection site suggested that the efficacy of treatment could be reduced due to particle phagocytosis. The aim of the present study was to decrease particle phagocytosis and consequently improve protein delivery using stealth technology. PEGylated microparticles were prepared by the double emulsion solvent evaporation method using TROMS (Total Recirculation One Machine System). Before the uptake studies in monocyte-macrophage cells lines (J774 and Raw 264.7), the characterization of the microparticles developed was carried out in terms of particle size, encapsulation efficiency, protein stability, residual poly(vinyl alcohol) (PVA) and in vitro release. Microparticles of suitable size for intramyocardial injection (5 mu m) were obtained by TROMS by varying the composition of the formulation and TROMS conditions with high encapsulation efficiency (70-90%) and minimal residual PVA content (0.5%). Importantly, the bioactivity of the protein was fully preserved. Moreover, PEGylated microparticles released in phosphate buffer 50% of the entrapped protein within 4 h, reaching a plateau within the first day of the in vitro study. Finally, the use of PLGA microparticles coated with PEG resulted in significantly decreased uptake of the carriers by macrophages, compared with non PEGylated microparticles, as shown by flow cytometry and fluorescence microscopy. On the basis of these results, we concluded that PEGylated microparticles loaded with VEGF could be used for delivering growth factors in the myocardium.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectPEGes_ES
dc.subjectPLGAes_ES
dc.subjectMacrophage uptakees_ES
dc.subjectVEGFes_ES
dc.subjectProtein deliveryes_ES
dc.titlePEGylated-PLGA microparticles containing VEGF for long term drug deliveryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.type.driverinfo:eu-repo/semantics/articlees_ES
dc.identifier.doihttp://dx.doi.org/ 10.1016/j.ijpharm.2012.07.006es_ES

Files in This Item:
Thumbnail
File
Simon at al-Figure 3.tif
Description
Size
337 kB
Format
TIFF
Thumbnail
File
Simon et al-Figure 1.tif
Description
Size
625.1 kB
Format
TIFF
Thumbnail
File
Simon et al-Figure 2.tif
Description
Size
108.07 kB
Format
TIFF
Thumbnail
File
Simon et al-Figure 4.tif
Description
Size
79.21 kB
Format
TIFF
Thumbnail
File
Simon et al-Tables.pdf
Description
Size
58.46 kB
Format
Adobe PDF
Thumbnail
File
Simon et al-Manuscript.pdf
Description
Size
138.88 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.